本研究的目的為探討作為已知的藥物篩選之用的『個人化精準醫療囓齒類PDX平台』，以及在台灣進行商業化服務的可行性。對於『個人化精準醫療囓齒類PDX平台』，本研究中顯示此平台具有提供醫師判斷藥物選擇資訊的能力，過半的受訪者表示在罹患癌症時願意使用此平台，心理預期願意支付的價格會因為得知預設平台使用費(45萬或55萬)資訊而隨之提高，此外，性別對於服務平台的心理預期價格有顯著差異，但對於使用平台的意願度沒有差異性。家庭總收入對使用意願有顯著的影響，但當獲知預設平台使用費用後，家庭總收入對使用意願的影響性即消失。『個人化精準醫療囓齒類PDX平台』則因面臨模式建構時間較長的技術限制，並有斑馬魚與類器官等替代平台的競爭可能，但依然是目前公認的藥物測試與篩選平台獲得較高信任度。因此強化價值鏈環節，保持平台技術與專業性的領先性，對於投入此市場的公司保持持續競爭力極具重要性。

The aim of the study was to investigate the feasibility of the rodent PDX (patient-derived xenograft) model platform on personalized and precision medicine in Taiwan. he results demonstrated that the Rodent PDX model can provide useful information of choosing target drugs for Hospital doctors and more than half of the respondents showed their intentions on using rodent PDX platform while they are suffering from cancer. Their expected prices for PDX platform were increased while receiving the set prices. The anchor effect on pricing was discovered. Moreover, gender effect was found on expected price but not on the intention of using the platform. The household income significantly affected the intention of using the platform. However, once respondents got the information of the set prices, their household income effect has disappeared. On the other hand, the establishment of rodent PDX model takes times and it encounters the competitions from Zebra fish PDX model and Organoid platform. Nevertheless, rodents PDX platform are still publicly accepted as a platform for drug assessments with trust. From the strategy point of view, in the early stage of the market development, the patients in stage III or IV who would like to use PDX model platform can be seen as rare resource while reviewing the number of patients using target drugs, considering the percentage of willing using PDX model from the results of this study and the dominance from hospitals. Therefore, the company that would like to enter the market, it should gain as much market share as possible with its higher professional skills to convince hospitals and patients. However, the number of company/organization entering the market could be increased in the long term because more target drugs will be developed and used in the future. The market structure may be changed from Oligopoly market to fully competitive market. In order to maintain its advantage and avoid the coming of fully competitive market, strengthening each section of company’s value chain and keeping its leading role in profession skills is suggested.

Baldwin, C. Y., Magretta, J., & Clark, K. B. (2000). Harvard business review on managing the value chain. In The Harvard business review paperback series (pp. 1 online resource (v, 271 p).
Barney, J. B. (1991). Firm resources and sustained competitive advantage. [S.l.]: [s.n.].
Byron, S. (1991). Competitive Marketing Strategy: Porter Revisited. Marketing Intelligence & Planning, 9(1), 4-10. doi:doi:10.1108/02634509110139556
Chijiwa, T., Kawai, K., Noguchi, A., Sato, H., Hayashi, A., Cho, H., . . . Nakamura, M. (2015). Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Int J Oncol, 47(1), 61-70. doi:10.3892/ijo.2015.2997
Cho, S. Y., Kang, W., Han, J. Y., Min, S., Kang, J., Lee, A., . . . Park, H. (2016). An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. Mol Cells, 39(2), 77-86. doi:10.14348/molcells.2016.2350
DiMasi, J. A., Reichert, J. M., Feldman, L., & Malins, A. (2013). Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther, 94(3), 329-335. doi:10.1038/clpt.2013.117
Flanagan, S. P. (1966). 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet Res, 8(3), 295-309.
Gidlund, M., Orn, A., Pattengale, P. K., Jansson, M., Wigzell, H., & Nilsson, K. (1981). Natural killer cells kill tumour cells at a given stage of differentiation. Nature, 292(5826), 848-850.
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug resistance in cancer: an overview. Cancers (Basel), 6(3), 1769-1792. doi:10.3390/cancers6031769
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goere, D., Mariani, P., . . . Berthet, C. (2012). Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res, 18(19), 5314-5328. doi:10.1158/1078-0432.CCR-12-0372
Kerbel, R. S. (2001). Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Rev, 20(1-2), 1-2.
Lee, E. J., Nam, G. H., Lee, N. K., Kih, M., Koh, E., Kim, Y. K., . . . Kim, I. S. (2018). Nanocage-Therapeutics Prevailing Phagocytosis and Immunogenic Cell Death Awakens Immunity against Cancer. Adv Mater. doi:10.1002/adma.201705581
Normann, R., & Ramírez, R. (1994). Designing interactive strategy : from value chain to value constellation. Chichester: Wiley.
Nunes, M., Vrignaud, P., Vacher, S., Richon, S., Lievre, A., Cacheux, W., . . . Dangles-Marie, V. (2015). Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. Cancer Res, 75(8), 1560-1566. doi:10.1158/0008-5472.CAN-14-1590
Organizing the Global Value Chain. Cambridge, Mass.: National Bureau of Economic Research.
Periti, P., & Mini, E. (1989). Drug resistance in cancer: an overview of the clinical aspects. J Chemother, 1(1), 5-9.
Porter, M. E. (1980). Competitive Strategy: Techniques for Analyzing Industries and Competitors.
Porter, M. E. (1985). Competitive advantage : creating and sustaining superior performance. London: Collier Macmillan.
Porter, M. E. (1998). Competitive strategy : techniques for analyzing industries and competitors : with a new introduction. New York: Free Press.
Rogers, E. M. (2003). Diffusion of innovations (5th ed ed.). New York: Free Press.
Rueff, J., & Rodrigues, A. S. (2016). Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint. Methods Mol Biol, 1395, 1-18. doi:10.1007/978-1-4939-3347-1_1
Rygaard, J. (1969). Immunobiology of the mouse mutant "Nude". Preliminary investigations. Acta Pathol Microbiol Scand, 77(4), 761-762.
Rygaard, J., & Povlsen, C. O. (1969). Heterotransplantation of a human malignant tumour to "Nude" mice. Acta Pathol Microbiol Scand, 77(4), 758-760.
Sabri, E. H., & Shaikh, S. N. (2010). Lean and agile value chain management a guide to the next level of improvement. In (pp. 1 online resource (473 p).
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018). Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med, 10(426). doi:10.1126/scitranslmed.aan4488
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007). Humanized mice in translational biomedical research. Nat Rev Immunol, 7(2), 118-130. doi:10.1038/nri2017
Sviokla, J. F. R. (1995). Exploiting the Virtual Value Chain. Harvard Business Review(NOVEMBER–DECEMBER).
Talmadge, J. E., Meyers, K. M., Prieur, D. J., & Starkey, J. R. (1980). Role of NK cells in tumour growth and metastasis in beige mice. Nature, 284(5757), 622-624.
Xu, Y. R., Li, Y. H., Chen, S. P., Zou, B. H., Zhang, Q., Xu, M., . . . Hu, L. D. (2015). [Establishment of Humanized Mouse Model by Using Transplantation of Mobilized Peripheral Blood Stem Cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 23(6), 1753-1757. doi:10.7534/j.issn.1009-2137.2015.06.040

網路文獻資料:
1. 105年死因統計結果分析 https://www.mohw.gov.tw/dl-37528-d087f641-de68-4c79-81d6-393f22a3962d.html (2017/11/27)
2. 103年十大死亡原因統計資料https://dep.mohw.gov.tw/DOS/lp-1779-113.html (2017/11/27)
3. 103年各類癌症健保前10大醫療支出統計 https://www.nhi.gov.tw/DL.aspx?sitessn=292&u=LzAwMS9VcGxvYWQvMjkyL3JlbGZpbGUvMC8yMjEwOC8xMDPlubTlkITpoZ7nmYznl4flgaXkv53liY0xMOWkp%2bmGq%2beZguaUr%2bWHuue1seioiC0xMDUwODI1LnBkZg%3d%3d&n=MTAz5bm05ZCE6aGe55mM55eH5YGl5L%2bd5YmNMTDlpKfphqvnmYLmlK%2flh7rntbHoqIgtMTA1MDgyNS5wZGY%3d&ico%20=.pdf (2018/1/16)
4. 103年度可支配所得、消費支出及儲蓄 https://win.dgbas.gov.tw/fies/doc/result/103/a11/Year09.xls (2018/1/11)
5. 103年家庭收支調查報告.http://win.dgbas.gov.tw/fies/doc/result/103.pdf (2017/11/31)
6. 105年死因統計年報， 衛生福利部統計處https://dep.mohw.gov.tw/DOS/lp-3352-113.html (2017/11/27)
7. MARKETSANDMARKETS, "Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022" https://www.marketsandmarkets.com/Market-Reports/patient-derived-xenograft-model-market-121598251.html (2018/3/9)
8. The Jackson Laboratory https://www.jax.org/jax-mice-and-services/in-vivo-pharmacology/oncology-services/pdx-tumors (2018/3/9)
9. 中美冠科生物科技股份有限公司 https://www.crownbio.com/oncology/in-vivo-services/patient-derived-xenograft-pdx-tumor-models (2018/3/9)
10. 中華民國103年癌症登記報告 https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=7330 (2017/11/27)
11. 戶數五等分位組之平均每戶可支配所得 https://win.dgbas.gov.tw/fies/doc/result/103/a11/Year03.xls (2018/1/11)
12. 戶數結構表(95) 家庭戶數, 內政部戶政司統計資料, http://www.ris.gov.tw/eu/346 (2018/1/11)